Severe everolimus-associated pneumonitis in a renal transplant recipient.
Inhibitors of mTOR (mammalian target of rapamycin) are immunosuppressants with less nephrotoxic potential than calcineurin inhibitors and antiproliferative effects, which are advantageous in the case of malignancy. However, a series of adverse events has been reported with the first-generation mTOR inhibitor sirolimus that includes hypersensitivity-like interstitial pneumonitis. To our knowledge, only one case of a pneumonitis associated with everolimus in a heart transplant patient has been reported, and it was related to elevated trough blood levels. We report herein the first case of a kidney graft recipient who developed everolimus-associated pneumonitis with normal trough blood levels that was completely reversed after drug withdrawal.
Alexandru
Simona
S
Nephrology Unit, Fundación Jiménez Díaz-Capio, Av Reyes Catolicos 2, 28040 Madrid, Spain. salexandru@fjd.es
Ortiz
Alberto
A
Baldovi
Sonia
S
Milicua
Jose Maria
JM
Ruíz-Escribano
Elena
E
Egido
Jesús
J
Plaza
Juan José
JJ
D000068338:Everolimus; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000097:blood; D007676:Kidney Failure, Chronic / Q000097:blood / Q000188:drug therapy / Q000601:surgery; D016030:Kidney Transplantation / Q000009:adverse effects; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000175:diagnosis / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D011494:Protein Kinases / Q000187:drug effects; D011859:Radiography; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood; D058570:TOR Serine-Threonine Kinases
D007166:Immunosuppressive Agents; D000068338:Everolimus; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus